Clinical Trial Update: An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B [Phase 1]

View source ↗

Summary

This is an open-label, single-dose Phase 1 pharmacokinetic study of Benefix (recombinant factor IX) in male Chinese subjects with Hemophilia B; results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BeneFIX (recombinant coagulation factor IX concentrate)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia B | Phase 1 | Status: COMPLETED | Results posted: 2016-07-25